120 results about "Phosphatidylglycerol" patented technology

The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s).

Particles having a tap density less than about 0.4 g/cm3 are formed by spray drying from a colloidal solution including a carboxylic acid or salt thereof, a phospholipid, a divalent salt and a solvent such as an aqueous-organic solvent. The colloidal solution can also include a therapeutic, prophylactic or diagnostic agent. Preferred carboxylic acids include at least two carboxyl groups. Preferred phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phophstidylserines, phosphatidylinositols and combinations thereof. The particles are suitable for pulmonary delivery.

Synthetic pulmonary surfactant compositions comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid are provided. Methods for treating respiratory disease are also provided comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid.

The invention relates to a cucurbitacin liposome composition and its preparation, which has rather high encapsulation efficiency, and can be administered through vein, muscle, oral and nasal. The constituent percentage by weight of the composition are, cucurbitacin BE or cucurbitacin B 0.001-0.1%, phospholipids 0.1-10%, cholesterin 0-5%, the phospholipids can be lecithin, di-stearoyl phosphatidyl choline, di- palmityl phosphatidyl choline, di-oleoyl phosphatidyl choline, di- palmityl phosphatidyl ethanolamine, di-stearoyl phosphatidylglycerol. The preparation according to the invention can be prepared in the form of injection, oral liquid, syrup, drop and nasal spray

The present invention provides a method for measuring activated partial thromboplastin time. The method comprises: a first mixing step of mixing a blood plasma with a first reagent, wherein the first reagent comprises an activator and phosphatidylglycerol at a concentration equal to or greater than 25 μg/mL; a second mixing step of mixing a sample obtained in the first mixing step with a second reagent comprising a calcium salt; and a step of measuring coagulation time of the sample obtained in the second mixing step.

The invention discloses a breviscapinum long-circulating nanoliposome and its preparation method, wherein the constituents include breviscapine, phosphatide, polyethylene glycol derived phosphatide (PEG2000-DSPE) and cholestrin by a molar ratio of 55:25-55:3-7:2.2-18.3, the dose type of the medicinal preparation includes injections, freeze-dried powder injections and sprays. The phospholipids can be soya bean lecithin, yolk phosphatidy icholine, hydrogenated soya bean lecithin, hydrogenated yolk lecithin, di-palmityl phosphatidyl choline or DPOG.

An alprostadil lipid emulsion for injection and a preparation method therefor. The lipid emulsion contains alprostadil, phosphatidylcholine, phosphatidylglycerol, oil for injection and a lyophilized protective agent. Based on 1 part by weight of the alprostadil, the content of the phosphatidylcholine is 1200 to 4000 parts by weight, the content of the phosphatidylglycerol is 12 to 120 parts by weight, the content of the oil for injection is 2000 to 20000 parts by weight, and the content of the lyophilized protective agent is 16000 to 60000 parts by weight.

The invention discloses a macromolecular phosphatidylglycerol nanoliposome, and preparation methods and applications thereof, and belongs to liposome preparation and application technologies. The phosphatidylglycerol nanoliposome is vesicles having a bilayer lipid membrane structure prepared by using phosphatidylglycerol chitosan to substitute phosphatide as a primary membrane material. The phosphatidylglycerol chitosan has a weight average molecular weight of above 2000, can be dissolved in organic solvents comprising chloroform, ethanol and the like, and contains a carboxyl or amino group. The preparation methods of the nanoliposome adopt common liposome preparation methods comprising a membrane dispersion method and an inverted evaporation method. The surface of like liposomes can be connected with a plurality of targeting preparations, and can simultaneously and respectively entrap water-soluble, oil-soluble or amphiphilic substances comprising medicines, proteins, genes, nutrients, vitamins, magnetic particles, quantum dots and the like. The methods have the advantages of high entrapment rate, simple operation, strong applicability and low cost, and the dressed macromolecular liposome has the advantages of uniform particle size distribution, adjustability in a range of 10-5000nm, stable system and strong slow release function.

The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a phosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug, and one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.

The present invention provides a propofol-containing fat emulsion comprising propofol, an oily component, and an emulsifier, and further comprising a predetermined amount of a stabilizer, such as phosphatidylglycerol in which a specific fatty acid is a constituent fatty acid component. The present invention also provides a pain-relieving propofol-containing fat emulsion, which is obtained by mixing a local anaesthetic in advance with the above-described propofol-containing fat emulsion of the invention.

Disclosed is a lipid preparation comprising a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The disclosed preparations possess an improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes, for example ADHD.

The invention discloses a phospholipid detection method and application. A phospholipid detection method is eluted with acetonitrile and ammonium acetate, and a phospholipid detection eluent comprisesacetonitrile and ammonium acetate, wherein by volume percentage, the acetonitrile accounts for 50% to 95%, and the ammonium acetate accounts for 5% to 50%. An application of the phospholipid detection method is used for detection of phosphatidylcholine, phosphatidylglycerol, phosphatidylserine, phosphatidyl ethanolamine, glycerophosphatidic acid, sphingomyelin and lysophosphatidylcholine. The analysis method provided by the invention has the advantages of simple operation, large number, good peak shape and short retention time of phospholipids analyzed, convenience and speed, reliability andpracticality.

The invention discloses disodium clodronate liposome injection and a preparation method thereof. The disodium clodronate liposome injection with excellent quality is made of disodium clodronate, distearoyl phosphatidyl glycerol, cholesterol, polyoxyethylene (40) hydrogenated castor oil according to specific weight ratio. Compared with the existing preparation, the injection has the advantages that the stability and the bioavailability of the injection are greatly improved, drug release is stable, the quality of injection products is improved, the toxic and side effect is reduced, and the curative effect is more obvious.

The invention discloses an ornithine aspartate liposome injection. The injection mainly comprises the following active ingredients: ornithine aspartate, dipalmitoyl phosphatidyl glycerol, cholesterol and antioxidant in part by weight of 1:3-20:1.8-12:0.05-0.2. The stability of the ornithine aspartate is improved; the valid period is prolonged; and the quality of the product is guaranteed. Because the liposome carriers, namely the dipalmitoyl phosphatidyl glycerol and the cholesterol, are degradable in bodies, the bioavailability is improved and the toxic and side effects are reduced. The injection has the advantages of simple production process, easy operation, low cost, high yield and suitability for mass production.

A method for predicting the level of epicardial adipose tissue (EAT) in a subject comprising: (a) determining a level of one or more lipid biomarkers in a sample from the subject, wherein the biomarkers are selected from the following: (i) phosphatidylcholine (PC) [16:1/16:1] (ii) diacylglycerol (DAG) [42:8] (iii) phosphatidylethanolamine-ether (PE-O) [32:5] (iv) phosphatidylcholine (PC) [18:0/22:5] (v) phosphatidylinositol (PI) [18:0/16:1] (vi) phosphatidylglycerol (PG) [20:3/20:3] (vii) phosphatidylglycerol (PG) [22:5/18:1] (b) comparing the levels of the biomarkers in the sample to reference values; wherein the levels of the biomarkers in the sample compared to the reference values are indicative of levels of EAT fat in the subject.

An isolated caveolin containing vesicle comprising a caveolin protein and at least one lipid, wherein at least about 30% of the at least one lipid is selected from phosphatidylethanolamine and phosphatidylglycerol is disclosed. Also disclosed is a method of making an isolated caveolin containing vesicle, an isolated caveolin containing vesicle comprising a recombinant caveolin protein, an isolated caveolin containing delivery vesicle, a method of making an isolated caveolin containing delivery vesicle and a method of treatment of a disease or condition by delivery of a molecule using the isolated caveolin containing delivery vesicle.

Inflammation and vascular abnormalities of the eye, including those related to ischemia, its prophylaxis and its alleviation, are treated by administration to the mammal of small amounts of phosphate-glycerol group presenting bodies such as phosphatidylglycerol liposomes.

The invention discloses a clevidipine butyrate liposome preparation and a preparation method thereof. The preparation includes 0.05wt%(wt%)-0.1%(wt%) of clevidipine butyrate, 40%(wt%) -70%(wt%) of phosphatidylcholine, 10%(wt%)-40%(wt%) of phosphatidyl glycerol, 10%(wt%)-30%(wt%) of sterol, and 0.55%(wt%)-3.3%(wt%) of stabilizer. The stabilizer contains a component A and a component B, wherein the component A is selected from one or more of oleic acid, sodium oleate, linoleic acid and sodium linoleate; and the component B is selected from one or more of vitamin E, coenzyme Q10, propyl gallate and ascorbyl palmitate. The liposome prepared by the method is in the form of liquid, and can be stored for a long time, therefore not only the potential safety hazard due to use of middle-chain and long-chain triglyceride in the traditional clevidipine butyrate emulsion is thoroughly solved, but also the freeze-drying operation in the traditional liposome preparation is omitted and the production cost is reduced; moreover, the liposome preparation is convenient for clinical application, overcomes the defect of uneven quality of redissolved freeze-drying liposome preparation and is beneficial to increase of the compliance and the medication safety of a patient.